[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hamad Medical Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":404},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,51,83,115,147,174,201,221,252,278,303,328,352,382],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100619994","effects-of-pemm-in-chronic-low-back-pain-women-with-urinary-incontinence-100619994",false,"NCT07351851","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence A Randomised Controlled Trial","Inclusion Criteria:\n\n* Age group of 18 - 65 years\n* Has child\u002Fchildren \\\u003C5 parity\n* CLBP patients with UI referred for physiotherapy for CLBP\n* Patient with low back pain for more than 3 months\n* NRS more than 5\u002F10\n* Patient with complain of urinary incontinence since past 3 months or more\n\nExclusion Criteria:\n\n* Chronic Low Back Pain with red flags\n* Not able to read and write in English \u002FArabic\n* Pregnant ladies and post partum 1 year\n* UTI, Pelvic floor Surgery\n* Any systemic condition of renal and cardiac\n* Patient with active carcinoma or any inflammatory disease","FEMALE","18 Years","65 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Urinary incontinence (UI), Chronic low back pain (CLBP) in women are prevalent and often coexist. Multiple conditions when coexist, it leads to reduced Quality of life in turn causing physical and mental impairment. Musculoskeletal structures and fascial restrictions is one of the attribute to the coexistence of urinary incontinence and chronic back pain in women. External myofascial mobilization (EMM) with core exercises have been proven beneficial for conditions in males that is caused by musculoskeletal and fascial structures. However there are limited research which proves the effect of EMM in conditions involving musculoskeletal and fascial structures . Therefore, the aim of the study is to find the effect of MFTs in reducing the disability in women with CLBP and UI PRIMARY OBJECTIVE To evaluate the effectiveness of PEMM treatment in reducing disability, pain and improving mental health in women with CLBP and UI Study design : Simple randomization Sampling method: Simple Random sampling Random numbers will be generated in Excel, then random numbers will be presented in a concealed envelope for the participants to choose Sample Size : 130 (Experimental 65, Control 65) Sample size was determined using expected effect size i.e., mean change in the primary outcome variable disability index reported in the recent research study . With effect size (change in the disability index score) 3.5 and standard deviation of the change in the outcome 6.45, statistical power 80% and level of significance 5%, the required sample size would be n=55 participants in each group. However, to accounts for multiple secondary outcome measures, possible dropouts and non-response it would be good to increase an additional 20% in calculated sample size i.e., a total of 130 participants (65 participants in each group) will be included in this study.\n\nThe following sample size equation was used to determine adequate sample size:n = \\[2 (Z?\u002F2 + Z?)2 \\* ?2\\] \u002F (m1-m2)2 Where Z? and Z? are the values standard normal variate e.g., at 5% level of significance Z?\u002F2 = 1.96, and with 80% power the value of Z?= 0.84; ? is the polled Standard deviation and m1 and m2 are the mean outcome values s in group 1 and group 2 respectively.\n\nBlinding:\n\nSingle blinding: patient will be blinded to the group allocation. The assessor is blinded to the treatment\n\nMaterial and tools :\n\nTheragun - Theragun Elite, 20 V, Myofascial tools - foam roll, foam ball, Questionnaires - SF 3642,43,44, Oswestry Low back pain questionnaire (ODI)45 and The International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI-SF)46 PROCEDURE In the course of the study the total number of patients referred to physiotherapy department with LBP will be interviewed to identify patients with or without UI having LBP. The data obtained from this will be recoded as prevalence in results. The documents of the patients having LBP with UI will be reviewed to check who fulfills the inclusion criteria. All who meets the inclusion criteria will be approached face to face with the aim of the study. Informed consent form will be given to patients who are volunteering to participate in the study. The data of the participants who do not wish to participate in the study will also be recorded.\n\nThe participants who have consented to participate in the study will be then assessed. Since the participants has UI she will be directed to a Urologist for an assessment. After urologist assessment, patients will be randomly allocated to experimental and control groups. Random allocation will be administered by the random numbers generated and will be presented in a concealed envelope for the participants to choose. 1st week, the demographic data and Outcome measure of pain, SF36, ODI, ICIQ-UI-SF will be recorded (1st time) on the day of assessment. The outcome measures will be printed on paper and will be given to the patients to fill up with a pen, all questionnaires are self reported outcome measures. Treatment will commence a week after, where experimental group will undergo PEMM therapy with strengthening for 6 weeks duration and the control group will have conventional symptomatic pain treatment with strengthening (2nd to 7th week). Treatment will be given for 6 weeks (1 sessions in a week). The treatment day may vary any day between 4th and 7th day post one session. After 6 sessions of treatment, patient will be advised HEP (Home exercise program) to continue at home. Reassessment will be done on the 8th week where the outcome measures of pain, SF36, ODI, ICIQ-UI-SF will be recorded. Participants will be educated and advised regarding HEP. Exercises will be taught to the patient by explanation, demonstration, teach-back method, and printed sheet of exercise. Compliance to HEP will be recorded before final Outcome measure",[27,28,29,30,31],"Chronic Low-back Pain (cLBP)","Urinary Incontinence (UI)","Pelvic External Myofascial Mobilisation","Myofascial Techniques","Pelvic Pain",[33,34,35,36,37],"chronic low back pain","urinary incontinence","myofascial mobilisation","PEMM","female pelvic pain","RECRUITING","2026-01-11",{"date":41,"type":42},"2026-01-20","ACTUAL",{"date":44,"type":42},"2025-09-29",{"date":46,"type":21},"2027-12",{"name":48,"class":49},"Hamad Medical Corporation","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100618560","scheduled-positioning-with-a-peanutballspp-on-labor-outcomes-among-primiparous-women-under-epidural-analgesia-100618560","NCT07333209","Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia","Determine the Impact of Scheduled Positioning With a Peanutball on Labor Outcomes Among Primiparous Women Under Epidural Analgesia: A Non-Invasive Randomized Controlled Trial","Peanutball","Inclusion Criteria:Inclusion Criteria:\n\nTo be eligible for participation, women must meet all the following criteria:\n\n* Primiparous (first pregnancy resulting in a live birth or stillbirth after 20 weeks of gestation).\n* Singleton at gestation.\n* Gestational age of the term (37 weeks 0 days to 41 weeks 6 days).\n* Admitted to the Labor and Delivery Unit at WWRC in active labor.\n* Received epidural analgesia for labor pain management.\n* Expected to have a vaginal delivery (e.g., no contraindications for vaginal birth identified at the time of recruitment).\n* Able to understand and communicate in Arabic or English.\n* Provide written informed consent.\n\nExclusion Criteria:The birthing ball should NOT be used in any of the following conditions:\n\n1. Obstetric Contraindications (Maternal)\n\n   * Any situation where vaginal birth is not appropriate (e.g., absolute indication for cesarean section)\n   * Non-progress of labor requiring immediate intervention\n   * Severe pre-eclampsia\u002Feclampsia\n   * Active vaginal bleeding of unknown cause\n   * Placenta previa (major) or vasa previa\n   * Placental abruption (suspected or confirmed)\n   * Preterm labor with medical contraindication to ambulation or mobility\n   * Ruptured membranes with unstable fetal head (high station) → Risk of cord prolapse\n   * Severe maternal exhaustion requiring bed rest\n   * Maternal hemodynamic instability\n2. Fetal Contraindications\n\n   * Non-reassuring fetal heart rate requiring continuous monitoring (Category II-III tracings)\n   * Malpresentation requiring immediate obstetric intervention (e.g., transverse lie)\n   * Suspected macrosomia with mechanical obstruction concerns (e.g., cephalopelvic disproportion)\n   * Multiple gestation with instability or complications\n3. Orthopedic \u002F Musculoskeletal Contraindications\n\n   * Any condition that prevents safe sitting, balancing, or weight-bearing, such as: Severe hips, leg, knee, or pelvic injuries\n   * Significant arthritis of the lower limbs or pelvis\n   * Recent joint surgery (hip\u002Fknee replacement, pelvic repair)\n   * Neuromuscular disorders affecting balance (e.g., severe neuropathy)\n   * Severe sciatica limiting mobility\n   * Poor trunk control or inability to maintain safe seated posture\n4. High-Risk Pregnancy Conditions\n\n   * Use of birthing balls is contraindicated if pregnancy is classified as high-risk, including Uncontrolled gestational diabetes and Uncontrolled hypertension\n   * Intrauterine growth restriction with required continuous monitoring\n   * Polyhydramnios or severe oligohydramnios (risk of cord compression\u002Finstability)\n   * Preterm premature rupture of membranes (PPROM)\n   * History of preterm birth with current instability\n   * Any condition requiring bed rest or reduced mobility\n5. Safety \u002F Environmental Contraindications\n\n   * Patients are unable to follow instructions or unsteady balance\n   * No trained staff available to supervise during labor use Unstable or improperly sized birthing ball","16 Years","55 Years",{"count":62,"type":21},110,[24],"Brief Summary\n\nThe goal of this clinical trial is to evaluate whether scheduled maternal position changes using a peanut birthing ball improve labor outcomes in low-risk, primiparous women receiving epidural analgesia during labor. The main questions it aims to answer are:\n\nDoes scheduled maternal positioning with a peanut ball reduce the duration of the first and second stages of labor?\n\nDoes scheduled maternal positioning with a peanut ball influence mode of delivery and maternal and neonatal outcomes?\n\nThis non-invasive randomized controlled trial will be conducted at the Women's Wellness and Research Center in Qatar. Participants will be randomly assigned to either an intervention group receiving scheduled maternal position changes using a peanut birthing ball or a control group receiving standard intrapartum care without peanut ball use. Researchers will compare outcomes between the two groups to determine whether structured positioning with a peanut ball improves labor progression and delivery outcomes in women receiving epidural analgesia.\n\nParticipants in the intervention group will undergo scheduled position changes throughout labor using a peanut birthing ball, including left lateral, right lateral, semi-sitting, and Taylor positions, under the supervision of trained nursing and midwifery staff. Participants in the control group will receive routine intrapartum care following epidural analgesia without the use of a peanut ball or a structured positioning schedule.\n\nPrimary maternal outcomes include duration of the first and second stages of labor, mode of delivery, estimated blood loss, postpartum hemorrhage, use of oxytocin augmentation, degree of perineal trauma, and hospitalization cost. Neonatal outcomes include Apgar scores at 5 and 10 minutes, NICU admission, birth-related injuries, and umbilical cord blood pH. Findings from this study are expected to support evidence-based intrapartum care practices and inform clinical protocols for women receiving epidural analgesia.",[66],"Labor (Obstetrics)--Complications",[57,68,69,70,71,72,73,74],"Scheduled positioning","Primiparous women","Randomized controlled trial","Non-invasive intrapartum intervention","Maternal labor outcomes","Neonatal outcomes","Epidural Analgesia","2025-12-31",{"date":77,"type":42},"2026-01-12",{"date":79,"type":21},"2026-01-01",{"date":81,"type":21},"2026-06-30",{"name":48,"class":49},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":50},"100616584","efficacy-of-scalp-block-in-managing-post-subarachnoid-hemorrhage-headache-in-critically-ill-patients-a-single-centre-randomized-controlled-trial-100616584","NCT07307508","Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial","SAH-BLOCK","Inclusion Criteria:\n\n* All adults \\> 18 years who are admitted to the Surgical Intensive Care Unit (SICU) with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage, undergoing endovascular treatment of the aneurysm (coiling\u002Fflow diversion).\n\nExclusion Criteria:\n\n1. Patients with aSAH undergoing surgical craniotomy and aneurysmal clipping.\n2. Non-aneurysmal subarachnoid or other intracranial hemorrhage forms (e.g., Intracerebral hemorrhage).\n3. SICU admission Glasgow Coma Scale (GCS) of 13 or lower.\n4. WFNS Score 4 \u002F 5 or requiring mechanical ventilation for more than 24 hrs.\n5. Patients with known allergy to local anesthetics.\n6. Admission to ICU \\> 7 days after hemorrhage.\n7. Patients with a documented bleeding disorder.\n8. Patients with a history of chronic headache disorder or migraine.\n9. Pregnancy","ALL",{"count":92,"type":21},22,[24],"Subarachnoid hemorrhage (SAH) is a devastating neurological disorder associated with significant mortality and morbidity rates, arising not just from the hemorrhage itself but also because of the catastrophic multisystem sequelae that can accompany the condition.\n\nRupture of an intracranial aneurysm accounts for up to 85% of instances of SAH, occurring in approximately 3 to 25 people per 100,000 annually in most populations. Treatment of aneurysmal SAH (aSAH) includes prevention of re-bleeding, evacuation of space-occupying hematomas, management of hydrocephalus, and prevention of secondary cerebral insult. Severe headache is the predominant characteristic symptom of aSAH, developing almost instantaneously at ictus in 50% of cases and continuing into the first days. Its severity has a variety of physiological and psychological effects on the patient. Scalp blocks have been suggested to alleviate this headache in case series. However, there is no strong evidence supporting this intervention. In this study, we aim to assess the impact of scalp blocks on headache reduction in patients undergoing endovascular treatment of an aneurysm (coiling or flow diversion) with aneurysmal subarachnoid bleeding.",[96,97],"Aneurysmal Subarachnoid Hemorrhage (aSAH)","Headache Disorders",[99,100,101,102,103,104,105,106],"Subarachnoid Hemorrhage Headache","Aneurysmal Subarachnoid Hemorrhage","Cerebral Aneurysm","SAH-associated headache","Scalp Block","Levobupivacaine","Opioid Consumption","Neurocritical Care","2025-12-14",{"date":109,"type":42},"2025-12-29",{"date":111,"type":42},"2025-10-22",{"date":113,"type":21},"2026-12-30",{"name":48,"class":49},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":132,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100613772","optimizing-enteral-nutrition-regimen-for-critically-ill-patients-100613772","NCT07270939","Optimizing Enteral Nutrition Regimen for Critically Ill Patients","Optimizing Enteral Nutrition: A Comparative Study of 18-Hour, 20-Hour, and 24-Hour","Inclusion Criteria\n\nParticipants must meet ALL of the following criteria to be eligible for the study:\n\n1. Patients aged ≥ 18 years.\n2. Patients expected to require enteral nutrition (EN) for ≥ 7 days.\n3. Critically ill, mechanically ventilated patients in the ICU.\n4. New patients initiating EN in the critical care unit.\n5. Patients receiving EN via:\n\n   * a nasogastric (NG) tube.\n   * orogastric (OG) feeding tube.\n\nExclusion Criteria:\n\n1. Patients with contraindications to enteral feeding or pre-existing gastrointestinal disorders, including:\n\n   * Active GI bleeding.\n   * Progressive GI disease.\n   * Recent GI tract resection.\n2. Indication for a special diet formula.\n3. Need for a large volume of feeding (as determined by the clinical team).\n4. Pre-existing hepatic failure.\n5. Use of a nasojejunal tube, gastrostomy, or jejunostomy.\n6. Pregnancy confirmed via β-hCG testing for women of childbearing potential.\n7. Insulin-dependent diabetes mellitus.",{"count":123,"type":21},150,[24],"Clinical Trial The goal of this clinical trial is to learn whether different enteral feeding cycles (18-hour, 20-hour, or standard 24-hour continuous feeding) improve outcomes for critically ill ICU patients who need tube feeding. It will also look at tolerance, nutrition delivery, and safety.\n\nThe main questions it aims to answer are:\n\nDo shorter feeding cycles (with fasting windows) reduce ICU length of stay?\n\nDo they lower the risk of infections like ventilator-associated pneumonia?\n\nHow do they affect calorie delivery, blood sugar control, and gastrointestinal tolerance?\n\nResearchers will compare:\n\nContinuous 24-hour feeding (standard care)\n\n20-hour feeding with a 4-hour fasting window\n\n18-hour feeding with a 6-hour fasting window\n\nParticipants will:\n\nBe critically ill adults in the ICU who require at least 7 days of enteral feeding\n\nBe randomized to one of the three feeding schedules\n\nReceive daily monitoring of calories, protein, blood sugar, and GI tolerance\n\nHave outcomes measured, including ICU length of stay, infections, metabolic control, and feeding tolerance",[127,128,129,130,131],"Critical Illness","Enteral Nutrition","Ventilator Associated Pneumonia","Hyperglycemia","Feeding Intolerance",[133,134,135,136,137],"Cyclic feeding","Feeding window","Critical care nutrition","Gastrointestinal tolerance","Nutritional adequacy","NOT_YET_RECRUITING","2025-11-26",{"date":141,"type":42},"2025-12-08",{"date":143,"type":21},"2025-12-30",{"date":145,"type":21},"2026-11-30",{"name":48,"class":49},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":50},"100540991","deprescribing-intervention-for-patients-with-chronic-kidney-disease-100540991","NCT06324045","Deprescribing Intervention for Patients With Chronic Kidney Disease","Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients who are:\n\n* diagnosed with ESRD receiving hemodialysis treatment or pre-dialysis patients who are followed up at a low clearance clinic.\n* receiving treatment at one of the ambulatory kidney centers in Qatar for at least two months.\n* able to communicate in Arabic and\u002For English.\n\nExclusion Criteria:\n\n* Unstable or has a psychiatric condition.\n* Presents with uncontrolled behaviors or exit-seeking behaviors (i.e., seeking to leave the premises out of confusion, frustration, or anger).\n* Critically ill patients, pregnant women, children, mentally ill, dementia, and unconscious patients.\n* Patients with limited life expectancy (less than 6 months).",{"count":155,"type":21},424,[24],"Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is associated with multiple consequences such as cardiovascular diseases, infections, reduced cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the population suffers from CKD. Management of CKD is associated with polypharmacy (the use of multiple medications), which burdens the patients and leads to adverse health and economic outcomes. As documented by previous studies, CKD setting is associated with a high medication burden, which leads to non-adherence, reduced quality of life, and other negative sequelae. These consequences can be minimized or averted by implementing a deprescribing program. Deprescribing is defined as the supervised process of intentionally stopping a medication, altering the dose or introducing a safer alternative to improve a person's clinical and quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient hospital settings were successfully implemented.\n\nIn general, there are limited deprescribing initiatives in CKD settings. There is a need to provide evidence of the impact of deprescribing programs on improving clinical and economic outcomes in this setting. In Qatar, there is no evidence of the effectiveness of implementing deprescribing programs in clinical settings. Therefore, we have built a team of researchers, clinicians, and stakeholders, and initiated a collaboration with deprescribing experts to fit into the Qatar healthcare system. This project aims to initiate a deprescribing multidisciplinary team and to evaluate the impact of providing such services on the clinical and economic outcomes among CKD patients in Qatar using a randomized controlled trial approach. The findings could have a potential positive impact on the professional practice and patient safety represented by health and economic outcomes.",[159],"Chronic Kidney Diseases",[161,162,163,164,165],"Deprescribing","Inappropriate polypharmacy","Treatment burden","Multidisciplinary","Clinical pharmacy","2025-09-26",{"date":168,"type":42},"2025-10-01",{"date":170,"type":42},"2024-02-19",{"date":172,"type":21},"2026-03",{"name":48,"class":49},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":18,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":50},"100605599","the-effectiveness-of-occupation-based-bilateral-arm-training-on-motor-functions-and-activity-participation-among-stroke-survivors-during-inpatient-rehabilitation-100605599","NCT07164612","The Effectiveness of Occupation-based Bilateral Arm Training on Motor Functions and Activity Participation Among Stroke Survivors During Inpatient Rehabilitation.","The Effectiveness of Occupation-based Bilateral Arm Training on Motor Functions and Activity Participation Among Stroke Survivors During Inpatient Rehabilitation. A Randomized Control Trial","Inclusion Criteria:\n\n1. Diagnosed with first ischemic or hemorrhagic stroke by medical physician\n2. Stroke onset ≤ 6 months\n3. Both males and females with age 18-65 years\n4. Cognitive functions within normal and mild deficit (MMSE ≥ 22)\n5. With arm and hand upper extremity Brunnstrom stage of \\>3\n6. Free of any other neurological diseases.\n\nExclusion Criteria:\n\n1. participants with previous stroke\n2. musculoskeletal disease or sever pain affecting the upper extremities\n3. participant who have taken part in another rehabilitative research\n4. sever visual neglect or visual field deficit.",{"count":123,"type":21},[24],"People with stroke often experience limitations in motor functions and activity participation. Occupation-based bilateral upper limb training (OBBT) using occupations as meaningful daily activities, and as part of the therapy. The activities in OBBT are tailored to the patient's life with the goal of boosting motivation and engagement to enhance activity performance and participation. This study is a randomized control trial that aims to explore the effect of OBBT along with the conventional therapy in comparison with the conventional therapy alone on motor functions and activity participation among stroke survivors in inpatient rehabilitation setting. This study will be conducted in Qatar Rehabilitation Institute, Hamad Medical Corporation, Doha, Qatar. Participants will be allocated randomly to either the OBBT group or the conventional therapy group. Participants in the OBBT group will receive 30 minutes OBBT program in addition to conventional therapy (90 minutes). Intervention sessions will be conducted 5 times per week over 6 weeks. The participants in the conventional therapy group will receive only the conventional therapy (90 minute). All participants will be assessed using the outcome measure immediately the day after completing the last intervention session at 4th week and 6th week.",[185],"Stroke",[185,187,188,189,190,191,192],"Occupations","Occupation-based intervention","Occupational Therapy","Motor Activity","Motor Skills","Patient Participation","2025-09-16",{"date":195,"type":42},"2025-09-22",{"date":197,"type":21},"2025-09",{"date":199,"type":21},"2027-09",{"name":48,"class":49},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":50},"100509542","impact-of-early-antibiotics-on-non-traumatic-out-of-hospital-cardiac-arrest-ohca-100509542","NCT05914779","Impact of Early Antibiotics on Non-Traumatic Out of Hospital Cardiac Arrest (OHCA)","Inclusion Criteria:\n\n* ● Adults aged \\>18 years, presenting to HGH ED after out-of-hospital cardiac arrest\n\n  * Patients with low likelihood of infection as per the definitions provided above\n  * Ability to obtain informed consent from the subjects or their next of kin\u002Ffamily member\u002Flegal surrogate in case of incapacitation due to sedation, mechanical ventilation, etc. In case the next of kin is not available, an independent physician who is not a part of the investigative team will complete and sign the checklist as per HMC Policy \"RES 11026\\_Appendix 6.5\". (see section 4.1.3 for details) A member of the investigative team and a witness will also sign this form before the potential subject is enrolled in the study.\n\nExclusion Criteria:\n\n* Patients who have clear evidence of infection, as defined by criteria for the study.\n\n  * Patients who have received antibiotics within the last 1 week prior to admission.\n  * Patients with malignancy, except those who have been cured or in complete remission.\n  * Females with known pregnancy.\n  * Known immunocompromised states (including HIV\u002FAIDS, transplant recipients on immunosuppressant drugs, long-term \\[\\> 3 weeks of prednisone \\>5mg\u002Fday equivalent\\] steroid therapy).\n  * Patients on immunologic disease modifying agents (commonly known as \"biologics\")\n  * Patients considered \"brain-dead\" or \"vegetative state\"\n  * Patients transferred from another hospital, long term care facility or institution\n  * Neutropenia (total WBC \\\u003C1,500\u002Fmm3 or absolute neutrophil count of \\\u003C1,000\u002Fmm3)",{"count":208,"type":21},1000,[24],"Specific Aim : The specific aim is to conduct a randomized prospective clinical trial to determine whether no antibiotics in OHCA patients in the ED with very low likelihood of infection is non-inferior to early antibiotic treatment. Hypothesis a: 28-day all-cause mortality will be non-inferior in OHCA patients with very low likelihood of infection who do not receive antibiotic therapy compared with those who receive early antibiotic therapy Hypothesis b: There will be no difference in subsequent incidence of proven infections in the no antibiotics vs, early antibiotics groups Hypothesis c: There will be no difference in the length of ICU stay and overall hospital stay in the early antibiotics vs. no antibiotics groups",[212,213],"Infection, Bacterial","Out-Of-Hospital Cardiac Arrest","2025-04-01",{"date":216,"type":42},"2025-04-03",{"date":218,"type":42},"2023-03-01",{"date":75,"type":21},{"name":48,"class":49},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":251,"locationsCount":50},"100584324","enhancing-post-stroke-dysphagia-rehabilitation-100584324","NCT06887855","Enhancing Post-Stroke Dysphagia Rehabilitation","Enhancing Post-Stroke Dysphagia Rehabilitation Via the Synergistic Effects of Neuromuscular Electrical Stimulation, Neuromuscular Taping, and Swallowing Exercises: a Randomized Controlled Trial","Not exist","Inclusion Criteria:\n\n* Patients aged 18 - 75 years old,\n* Diagnosed with swallowing disorders between one day and six months post-stroke,\n* Able to attend 10 therapy sessions,\n* Have never received any swallowing treatment before participating in this study.\n\nExclusion Criteria:\n\n* Post-stroke patients with severe cognitive impairment,\n* Patients who have swallowing disorders due to other etiologies,\n* Patients who need traditional swallowing therapy other than Expiratory Muscle Strength Training (EMST) and Chin Tuck Against Resistance (CTAR). - Skin disorders in the submental area and anterior neck,\n* Medical conditions that may affect participation,\n* A defibrillator and use precision electrical biomedical devices (e.g. pacemaker, etc.).","75 Years",{"count":231,"type":21},10,[24],"The goal of this clinical trial is to investigate the effects of a combined swallowing intervention (Neuromuscular Electrical Stimulation (NMES) + Neuromuscular Taping (NMT) + swallowing exercises) on swallowing function and quality of life in post-stroke dysphagia patients. The main questions it aims to answer are:\n\n• Does the combination of swallowing exercises, NMES \\& NMT have a greater improvement in dysphagia rehabilitation when compared to either NMES or NMT alone? Researchers will compare the effects of intervention between the three groups (NMES and swallowing exercises, NMT and swallowing exercises, and NMES with NMT and swallowing exercises).\n\nParticipants will:\n\n* Receive a combined dysphagia rehabilitation comprised of swallowing exercises, Neuromuscular Electrical stimulation, and\u002For Neuromuscular Taping.\n* Visit the clinic once every 5 days a week for 10 therapy sessions.\n* Undergo baseline and post-intervention evaluation procedures.",[235],"Dysphagia After Stroke",[237,238,239,240,241,242,243,244],"post-stroke","dysphagia","combined rehabilitation","neuromuscular electrical stimulation","kinesiology taping","neuromuscular taping","chin tuck against resistance","expiratory muscle strength training","2025-03-15",{"date":247,"type":42},"2025-03-20",{"date":249,"type":42},"2024-11-01",{"date":143,"type":21},{"name":48,"class":49},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":259,"sex":90,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":264,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100565499","development-validation-and-testing-of-an-education-program-for-identification-of-learning-disabilities-among-school-children-by-primary-school-teachers-in-qatar-100565499","NCT06642974","Development, Validation and Testing of an Education Program for Identification of Learning Disabilities Among School Children by Primary School Teachers in Qatar","LD - Learning","Inclusion Criteria:\n\n\\-\n\nInclusion Criteria:\n\nThe study will include:\n\n* Teachers who are teaching in private schools in state of Qatar\n* Teachers who are teaching Indian curriculum\n* Teachers who are teaching subjects such as English, mathematics, environmental science, and science\n* Teachers who can speak and write English.\n\nExclusion Criteria:\n\n* Teachers who are not willing to participate in the study",true,"30 Years","50 Years",{"count":263,"type":21},134,[24],"Aim The aim of this study to develop, validate and test an education program for identification of learning disabilities among school children by Primary school teachers in Qatar Objectives\n\n1. To develop and validate an education program on identification of learning disabilities of children by primary school teachers\n2. To evaluate the effectiveness of an education program regarding identification of learning disabilities of children.",[267],"Learning Disabilities, Child",[269],"Learning Disabilities, children","2024-10-21",{"date":272,"type":42},"2024-10-23",{"date":274,"type":21},"2024-10-25",{"date":276,"type":21},"2025-04-30",{"name":48,"class":49},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":90,"minAge":284,"maxAge":17,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":50},"100563931","the-effect-of-dietary-management-and-cysteine-supplementation-on-growth-parameters-and-biochemical-control-for-pediatric-qatari-patients-affected-with-classical-b6-non-responsive-homocystinuria-100563931","NCT06622577","The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric Qatari Patients Affected with Classical B6 Non-responsive Homocystinuria.","Inclusion Criteria:\n\n* All the patients with a confirmed diagnosis of HCU by molecular and biochemical testing who are either diagnosed through NBS or LD who are following the diet\n\n  * Both male and female gender from birth to 18 years\n  * Participants depending on the age of inclusion who are willing to participate\n\nExclusion Criteria:\n\n* ✔ Patients with Pyridoxine responsive- homocystinuria\n\n  * Patients who are solely on medication without any dietary intervention ✔ Non-Qatari Patients with a confirmed diagnosis of HCU","1 Day",{"count":286,"type":21},50,[24],"Classical homocystinuria (HCU) is an autosomal recessive disorder caused by the deficiency of an enzyme cystathionine β-synthase (CβS) that affects the catabolic pathway of the amino acid methionine (Met) which leads to an accumulation of high levels of methionine and Homocysteine causing complications in the multi system. Therefore, a strict dietary management is crucial to maintain good biochemical control, growth parameters and avoid complications. The main objective would be to analyze the impact of the Met restricted diet on growth parameters, biochemical markers and long-term complications in patients up to 18 years. In addition, the efficacy of dietary management with additional cysteine (Cys) supplementation for the patients up to 18 years would also be examined.\n\nThe participants of the study would be recruited from the metabolic and genetics clinic in Hamad General Hospital (HGH), Qatar. All Qatari participants with confirmed diagnosis of HCU \\<18 years of age will be included in the study. A mixed method study design would be used which include a cross sectional study design to assess the impact of methionine restricted diet on outcome variables and a single arm interventional study to analyze the effect of additional cysteine supplementation in patients from birth to 18 years. For the retrospective study, all the required data would be retrieved from electronic record from the Cerner of HMC and would be stored in a local drive with password protection. Further, all the eligible participants would be prospectively followed to supplement additional cysteine for the period of 6 months.\n\nThe collected data will be statistically analyzed using the \"SPSS windows version 22.0 software. The study would improve better understanding of dietary management through the identified outcomes. The outcome of Cys supplementation will improve the protein tolerance, biochemical parameters, growth parameters and may standardize the Cys supplementation.",[290],"Classical Homocystinuria",[292,293,294],"Methionine","Homocystinuria","cysteine","2024-09-30",{"date":297,"type":42},"2024-10-02",{"date":299,"type":21},"2024-12-01",{"date":301,"type":21},"2025-08-31",{"name":48,"class":49},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":259,"sex":90,"minAge":309,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":50},"100325915","phase-1-use-of-dexamethasone-in-prevention-of-the-second-phase-or-a-biphasic-reaction-of-anaphylaxis-100325915","NCT03523221","Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis","Inclusion Criteria:\n\n* All patients 3 monthes-14years presenting to the Pediatric Emergency Department (AlSadd) with mild to moderate anaphylaxis\n\nExclusion Criteria:\n\nPatients with severe anaphylaxis. Patient with history of immunological diseases. Patients on steroids therapy Patient with moderate-severe asthma on medication Patients with severe asthma","3 Months","14 Years",{"count":312,"type":21},210,[314],"PHASE1","Anaphylaxis is an acute serious allergic reaction, with multi-organ system manifestations caused by the release of chemical mediators and it is potentially fatal .\n\nBetween 5% and 14% of patients may experience a recurrence of anaphylaxis 8-12 hours after the initial presentation, called biphasic (late-phase) .\n\nThe mainstay of treatment for children experiencing anaphylaxis remains adrenaline and H1-antihistamines. Corticosteroids are not life-saving and do not have an immediate effect on the symptoms of anaphylaxis but may help reduce or prevent a biphasic \"late phase\" reaction .\n\nThe aim of this study is to compare the efficacy of oral glucocorticoids in prevention of the second phase or biphasic reaction of anaphylaxis, as compared to placebo in children, presenting to the pediatric emergency department (PEC Al-Sadd) with mild to moderate anaphylaxis (Prospective Study).\n\nPatients will be randomized to either one of the two treatment:\n\nTreatment 1: Dexamethasone 0.6mg\u002Fkg oral. Treatment 2 : Placebo All patients will be urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of the study medications orally, and he \u002Fshe will observe in the observation room with cardiac monitor and close monitoring by nurse.\n\nThe treating physician will discharge patient when he\u002Fshe looks well, breathing comfortably, has oxygen saturation \\>94%, stable blood pressure and no gastrointestinal or neurological manifestation.\n\nDischarge patients will be sent home on anti-histamine (cetirizine) for 5days. All patients will be followed up for one week post discharge by a phone call asking about the general condition, relapse of symptoms, or need for readmission.",[317],"Anaphylaxis",[319],"Mild -Moderate Anaphylaxis","2024-08-13",{"date":322,"type":42},"2024-08-14",{"date":324,"type":42},"2018-04-15",{"date":326,"type":21},"2024-12",{"name":48,"class":49},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":259,"sex":90,"minAge":17,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":50},"100558235","human-albumin-for-clinical-outcome-in-aneurysmal-subarachnoid-hemorrhages-100558235","NCT06548477","Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages","Effectiveness of Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages: A Protocol for Randomized Controlled (Hash) Trial.","HASH","Inclusion criteria\n\n* Age limits of participants will be between 18 and 80 years with either gender (male or female).\n* Clinical presentation with the first of symptom of aSAH must be within 72 hours before randomization.\n* Clinical manifestation must be suggestive of aSAH that may include classical thunderclap headache, cranial nerve deficits, changes in level of consciousness, neck rigidity and neurological deficits.\n* All cases with WFNS grade 1 to 5 (at the time of randomization) will be recruited in the study.\n* Head computed tomography demonstrates evidence of SAH (graded on Claassen's scale).\n* Diagnostic cerebral angiography shows a saccular aneurysm\u002Fs, consistent with clinical presentation of SAH.\n* Definitive treatment of ruptured aneurysm\u002Fs (with clipping or coiling of combined) must be carried out within 72 hours prior to randomization.\n* An informed consent by patient or surrogate representative, must be duly signed and dated.\n\nExclusion criteria\n\n* Timing of first symptom of SAH cannot be reliably ascertained.\n* Cerebral angiogram negative SAH.\n* Cerebral angiography showing mycotic\u002Ftraumatic\u002Ffusiform aneurysm\u002Fs.\n* Symptomatic vasospasm or angiographic (on TCD or CTA) sets in before recruitment within 72 hours.\n* History of clinical findings\u002Fhospitalization due to heart failure within the past 6 months,\n* Albumin administration prior to randomization in the same hospital admission.\n* History of acute myocardial infarction (MI) within past 3 months.\n* Any clinical presentations or electrocardiography (ECG) findings suggestive of acute MI on current admission.\n* ECG evidence and\u002For clinical findings of 2nd or 3rd degree heart block or arrhythmias causing hemodynamic changes.\n* Echocardiogram done before intervention\u002Frandomization showing an ejection fraction of \\\u003C40%.\n* A creatinine level of \\>2.0 mg\u002Fdl or a creatinine clearance of \\\u003C50 ml\u002Fmin\n* Pregnancy, lactation, or parturition within previous 30 days\n* Any allergies to any ingredient in human albumin preparation.\n* A prior severe physical disability (mRS \\>2) that may hamper assessment of clinical outcome.\n* Advanced chronic obstructive pulmonary diseases (with FEV1 \\\u003C50%) may manifest as frequent episodes significantly affecting the overall quality of life.\n* Hepatic failure or suspected liver dysfunction due to deranged liver functions, decreased serum albumin levels, high bilirubin levels with\u002Fwithout peripheral edema and hepatic encephalopathy.\n* Patient has been already enrolled in another study involving a drug administration.\n* Patient suffering from terminal diseases with life expectancy \\\u003C 6 months\n* If patient speaks any other language in which consent has not been translated.\n* In case, patient drops out\u002Fwithdraws from study or transferred out of state of Qatar and therefore lost to follow up short of 3-month follow up.","80 Years",{"count":338,"type":21},84,[24],"Aneurysmal subarachnoid hemorrhage (aSAH) is a dreadful acute neurological condition with overwhelmingly high rate of associated morbidities and mortality. Despite leaping advancement in neurosurgical techniques and imaging modalities, there is no substantiative improvement in overall prognosis for aSAH. Cerebral vasospasm remains the predominant cause of associated morbidities. Human albumin has been used in different neurological conditions including head trauma, intracerebral hemorrhages, and ischemic strokes with favorable outcome. However, its beneficial use in aSAH has not been sufficiently explored until recently a published systematic review by our team. In view of scarcity of published data and lack of robust evidence, our group has designed for the first ever RCT to compare the use human albumin-enhanced fluid management versus standard fluid therapy with crystalloids in patients with aSAH.\n\nThis single center open label, prospective, parallel group randomized control trial will be conducted at Hamad General Hospital, Doha-Qatar from August 2024 to July 2027. A sample size of 84 (42 in each arm) has been calculated to detect as sufficient to detect a clinically significant difference in modified Rankin Scale good score between two groups (human-albumin induced volume expansion therapy versus crystalloid only) for fluid management in aneurysmal subarachnoid hemorrhages patients. Primary outcome will be based on dichotomized modified Rankin scale \\[(Good grades (0-2) and poor grades (3-6)\\], while secondary outcome will include symptomatic vasospasm, transcranial doppler velocities, and Pulse Index Contour Cardiac Output (PiCCO) parameters.\n\nThe trial aims to provide firsthand evidence on the beneficial use of human albumin to achieve optimal fluid management regime to explore its potential role to improve clinical outcome in patients with aSAH.",[100],[343],"HASH trial, Human Albumin, Subarachnoid hemorrhage, Aneurysmal, Effectiveness, Clinical Outcome, Protocol","2024-08-09",{"date":346,"type":42},"2024-08-12",{"date":348,"type":21},"2024-08-01",{"date":350,"type":21},"2027-07-31",{"name":48,"class":49},{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":90,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":362,"conditions":363,"keywords":368,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":381},"100470541","therapeutic-plantar-electrical-stimulation-intervention-during-hemodialysis-to-improve-balance-and-mobility-100470541","NCT05407207","Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility","Inclusion Criteria:\n\n* Male and female patients with diabetes receiving dialysis who are \\>40 years old.\n* Ambulatory (able to independently walk 20m with or without walking assistance).\n* Willing and able to provide informed consent.\n* Diabetes will be defined based on the American Diabetes Association (ADA) criteria (83).\n* Evidence of peripheral neuropathy and its severity will be determined based on a neurologic examination using criteria explained in the ADA statement.\n\nExclusion Criteria:\n\n* Have an active foot ulcer, an active infection, Charcot neuroarthropathy, or major foot amputation.\n* Patients with any clinically significant medical or psychiatric condition, or laboratory abnormality that would, in the judgment of the investigators, interfere with the ability to participate in the study.\n* Patients concurrently participating in exercise training; major hearing\u002Fvisual impairment; any patient with changes in psychotropic or sleep medications in the last 6 weeks.\n* If they were unlikely to fully comply with the follow-up protocol (e.g., travel plans).","40 Years",{"count":360,"type":21},100,[24],"A high prevalence of diabetes has been reported in Qatar with nearly 23% population suffering from the pandemic, thereby increasing the associated healthcare cost. Low compliance with exercise and physical activity in patients with diabetes increases foot risk complications, deteriorates health, and further increases economic costs. This is particularly true among patients with diabetes who are undergoing hemodialysis (HD) process. Exercise interventions have been shown to improve mobility and balance, reduce the incidence of falls, and improve peripheral blood flow, which is essential to reduce foot problems and peripheral arterial disease. However, uptake of exercise programs for individuals who are undergoing HD treatment has been limited. The three main factors limiting uptake and adherence among HD patients are time availability, post-dialysis fatigue, and transportation to exercise programs, which are usually offered in rehabilitation departments or cardiovascular centers but not in nephrology departments or in free-standing dialysis clinics. Many of these patients visit clinics 3 times a week to receive hemodialysis, providing an optimal opportunity for intervention. Thus the investigators are proposing an innovative intervention based on plantar electrical stimulation treatment during HD (3 times per week) to enhance balance and quality of life while reducing the risk of peripheral arterial diseases and diabetic foot ulcers, which are highly prevalent among people with diabetes and chronic kidney disease. This interdisciplinary study is based on preliminary studies, in which the investigators demonstrated that regular plantar electrical stimulation is an effective and practical therapy to enhance motor performance and plantar sensation in patients with diabetes. The scientific premise of the proposed intervention has been also supported by literature as well as three systematic reviews suggesting the effectiveness of electrical stimulation to reduce pain, improve balance, improve skin perfusion, and improve plantar sensation. In the context of this study, the investigators propose to bring an innovative technology based on an FDA-cleared bio-electric stimulation technology (BEST®) microcurrent platform, named Tennant Biomodulator® (Avazzia Inc., Dallas, TX, USA), which is a transcutaneous electrical nerve stimulator (TENS) and has been designed for symptomatic relief and management of chronic pain. However, the system was modified to provide electrical stimulation to the plantar area via two electrodes placed on the hind and forefoot area instead of the leg. The device has a 60-minute run cycle after which it automatically turns off. In the context of a previous study funded by QNRF, the investigators developed and tested 50 electrical stimulation units (which will be used in the context of the study), including 25 active systems and 25 placebo systems. The placebo systems are similar to active systems in the appearance and functioning of lights and indicators. However, they were programmed not to provide any electrical current.\n\nIn a preliminary study, the proof of concept of this revised technology was tested in the context of enhancing balance and skin perfusion in ambulatory patients with diabetes and peripheral neuropathy. In the context of this study, the investigators plan to translate this technology for routine treatment during HD sessions for patients with diabetes who are undergoing regular HD treatment. Using a double-blinded randomized-controlled model, the investigators will validate the effectiveness of this technology to enhance balance, reduce pain, and improve skin perfusion. One hundred (n=100) HD volunteers with diabetes will be recruited and randomized to either intervention (n=50) or control (CG: n=50) group for the purpose of this study. Plantar electrical stimulation will be provided during HD sessions, 3 times per week and for 12 weeks. Outcomes will be assessed at baseline, 6 weeks, and 12 weeks to examine the effectiveness of the proposed intervention to enhance balance, improve quality of life, and improve lower extremity skin perfusion among HD patients with diabetes.\n\nThis proposal is in line with Qatar National Priorities Research goals and if successful the result will open new doors to managing diabetes and kidney failure. In a setting where no therapeutic agents or interventions effectively address poor balance and loss of protective sensation among HD patients with diabetes and where affected individuals life with a heightened risk of developing a debilitating foot ulcer and quite possibly a disabling amputation, the potential impact from the plantar electrical stimulation system may offer the potential for significant clinical benefit, with very low risk, and with ease of implementation in routine care application for patients who are undergoing HD treatment.",[364,365,366,367],"Diabetes Mellitus","Hemodialysis Complication","Cardiovascular Complication","Quality of Life",[369,370,371,372],"Preventive supplements","Treatment of diabetes related complications","Health intervention","Lifestyle intervention","2022-06-02",{"date":375,"type":42},"2022-06-07",{"date":377,"type":42},"2018-06-01",{"date":379,"type":21},"2022-11-11",{"name":48,"class":49},2,{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":390,"phases":4,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":50},"100316034","qatar-cardiometabolic-registry-100316034","NCT03394313","Qatar Cardiometabolic Registry","Inclusion Criteria:\n\n* Patients with type 2 diabetes mellitus\n* Newly diagnosed heart disease, such as ischemic heart disease, heart failure.\n\nExclusion Criteria:\n\n* Patients who do not have type 2 diabetes mellitus\n* Preexisting heart disease",{"count":389,"type":21},50000,"OBSERVATIONAL","Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are closely related. T2DM risk equivalent for CVD and it remains the major cause of death in T2DM. Thus, patients with T2DM and CVD disease are at very high-risk of CVD-related mortality. Therefore, more aggressive metabolic and hemodynamic control is required in such patients to improve the prognosis. We recently initiated a cardio-metabolic clinical service at the Heart Hospital, where T2DM patients with existing CVD are simultaneously examined by Cardiologist and Diabetologist for optimal metabolic and hemodynamic control. We would like to start a clinical registry for all patients who attend this clinical service to collect import clinical data about this population. This registry will serve an important source for future clinical research in the field.",[364,393],"Cardiovascular Diseases",[395],"Registry","2018-01-07",{"date":398,"type":42},"2018-01-09",{"date":400,"type":42},"2017-09-15",{"date":402,"type":21},"2027-12-31",{"name":48,"class":49},""]